Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China

Recent studies indicate that primary aldosteronism (PA) is a much more common cause of hypertension than had been demonstrated historically. In patients with resistant hypertension, the prevalence of PA from different clinics worldwide is about 10-20%. As has been no such data in China, the investigators are conducting a PA study in different province of China to evaluate the prevalence of PA in patients with resistant hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension, Resistant to Conventional Therapy Hypertension Resistant to Conventional Therapy

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Dep.endocrinology of Shanghai Ruijin Hospital, Shanghai Jiaotong university school of medcine

Shanghai, Shanghai Municipality, 200025, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with resistant hypertension
age 18-65 years

Exclusion criteria

known cause of hypertension
heart failure
renal dysfunction
Stroke, transient ischaemic attack or myocardial infarction in the past 6 months
cirrhosis
pregnancy
undertreatment of glucocorticoid

Sponsors and collaborators

Lead sponsor

Shanghai Jiao Tong University School of Medicine

Other

Registry information

Official study title

Prevalence of Primary Aldosteronism and Status of Renin-Angiotensin System in Resistant Hypertension:An Observational Study in China

Important dates

Study start: 2010
Primary completion: 2011
First posted: Oct 25, 2011
Registry last updated: Oct 25, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed